The stock is trading at $32.94 significantly above the 50 day moving average which is $25.01 and quite a bit higher than the 200 day moving average of $25.01. The 50 day moving average was up by +31.70% and the 200 day average was up $7.93. Trading volume for Aimmune Therapeutics, Inc. was 520K in the last trading session. Trading volume was up 41.80% over the stocks average daily volume.
Traders are more bullish on shares of Aimmune Therapeutics, Inc. recently as indicated by the fall in short interest. The firm realized a fall in short interest between September 15, 2017 and September 29, 2017 of -8.10%. Short interest decreased from 5,460,377 to 5,017,874 over that timeframe. With short interest at 5,017,874 and short average daily volume at 335,263, the short-interest ratio is 15.0 and the short interest percentage is 0.10% as of September 29.
There has been some selling insider activity on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) recently. Stephen George Dilly, President and CEO let go of $2,595,696 worth of shares at a price of $26.26 on Fri the 6th. That brings the President and CEO’s holdings to $10,936,292 as reported to the SEC. Stephen George Dilly, President and CEO sold $30,281 worth of shares at an average price of $26.24 on Mon the 16th. The President and CEO now owns $10,897,682 of the stock per an SEC filing yesterday.
These funds have shifted positions in (AIMT). Next Financial Group, Inc divested its investment by shedding 200 shares a decrease of 33.3% in the quarter. Next Financial Group, Inc currently owns 400 shares with a value of $8,000,000. The total value of its holdings increased 66,566.7%. As of the end of the quarter Vivo Capital, LLC had bought 13,804 shares growing its holdings by 1.8%. The value in dollars decreased from $16,580,000 to $15,971,000 decreasing 3.7% quarter over quarter.
Point72 Asset Management, L.p. bolstered its stake by buying 314,259 shares an increase of 46.1% as of 06/30/2017. Point72 Asset Management, L.p. claims 996,232 shares worth $20,483,000. The value of the position overall is up by 38.2%. As of quarter end Cutler Group LP had acquired a total of 1,200 shares growing its position 133.3%. The value of the investment in AIMT went from $18,000 to $11,000 a change of $7,000 for the reporting period.
October 23 investment analysts at Credit Suisse maintained a stock rating of “Outperform” but raised the price target from $35.00 to $45.00.
In the latest earnings report the EPS was $-2.25 and is estimated to be $-2.71 for the current year with 50,535,000 shares outstanding. Analysts expect next quarter’s EPS will be $-0.82 with next year’s EPS anticipated to be $-3.25.
Aimmune Therapeutics, Inc., launched on June 24, 2011, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Business’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Business’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy..